Enterprise Financial Services Corp (EFSC)’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-194
| Closed | -$204K | – | 159 |
|
|
2024
Q3 | $204K | Hold |
194
| – | – | 0.12% | 141 |
|
|
2024
Q2 | $204K | Buy |
+194
| New | +$188K | 0.13% | 146 |
|
|
2021
Q3 | – | Sell |
-123
| Closed | -$69K | – | 1019 |
|
|
2021
Q2 | $69K | Buy |
123
+108
| +720% | +$54.7K | 0.01% | 330 |
|
|
2021
Q1 | $7K | Sell |
15
-32
| -68% | -$15.6K | ﹤0.01% | 852 |
|
|
2020
Q4 | $22K | Buy |
47
+21
| +81% | +$11.3K | ﹤0.01% | 556 |
|
|
2020
Q3 | $15K | Buy |
26
+2
| +8% | +$1.21K | ﹤0.01% | 618 |
|
|
2020
Q2 | $15K | Sell |
24
-82
| -77% | -$46.5K | ﹤0.01% | 613 |
|
|
2020
Q1 | $52K | Buy |
106
+104
| +5,200% | +$42.9K | 0.01% | 346 |
|
|
2019
Q4 | $1K | Buy |
+2
| New | +$673 | ﹤0.01% | 1090 |
|
|
2019
Q3 | – | Sell |
-14
| Closed | -$4K | – | 1177 |
|
|
2019
Q2 | $4K | Buy |
14
+13
| +1,300% | +$4.33K | ﹤0.01% | 937 |
|
|
2019
Q1 | $0 | Hold |
1
| – | – | ﹤0.01% | 1223 |
|
|
2018
Q4 | $0 | Hold |
1
| – | – | ﹤0.01% | 1053 |
|
|
2018
Q3 | $0 | Buy |
+1
| New | +$381 | ﹤0.01% | 1057 |
|
|
2018
Q1 | – | Sell |
-6
| Closed | -$2K | – | 956 |
|
|
2017
Q4 | $2K | Sell |
6
-13
| -68% | -$5.26K | ﹤0.01% | 828 |
|
|
2017
Q3 | $8K | Buy |
19
+2
| +12% | +$952 | ﹤0.01% | 628 |
|
|
2017
Q2 | $8K | Hold |
17
| – | – | ﹤0.01% | 625 |
|
|
2017
Q1 | $7K | Sell |
17
-25
| -60% | -$9.27K | ﹤0.01% | 696 |
|
|
2016
Q4 | $15K | Buy |
42
+26
| +163% | +$9.89K | 0.01% | 520 |
|
|
2016
Q3 | $6K | Sell |
16
-5
| -24% | -$2.01K | ﹤0.01% | 702 |
|
|
2016
Q2 | $7K | Hold |
21
| – | – | ﹤0.01% | 640 |
|
|
2016
Q1 | $8K | Sell |
21
-6
| -22% | -$2.47K | ﹤0.01% | 596 |
|
|
2015
Q4 | $15K | Buy |
27
+5
| +23% | +$2.71K | 0.01% | 473 |
|
|
2015
Q3 | $10K | Buy |
22
+5
| +29% | +$2.69K | 0.01% | 545 |
|
|
2015
Q2 | $9K | Sell |
17
-4
| -19% | -$1.95K | 0.01% | 590 |
|
|
2015
Q1 | $9K | Buy |
21
+6
| +40% | +$2.54K | 0.01% | 650 |
|
|
2014
Q4 | $6K | Buy |
15
+5
| +50% | +$1.97K | ﹤0.01% | 755 |
|
|
2014
Q3 | $4K | Hold |
10
| – | – | ﹤0.01% | 840 |
|
|
2014
Q2 | $3K | Sell |
10
-3
| -23% | -$889 | ﹤0.01% | 964 |
|
|
2014
Q1 | $4K | Hold |
13
| – | – | ﹤0.01% | 884 |
|
|
2013
Q4 | $4K | Hold |
13
| – | – | ﹤0.01% | 835 |
|
|
2013
Q3 | $4K | Buy |
13
+3
| +30% | +$789 | ﹤0.01% | 819 |
|
|
2013
Q2 | $2K | Buy |
+10
| New | +$2.33K | ﹤0.01% | 856 |
|
Other funds holding REGN
Enterprise Financial Services Corp (EFSC)'s REGN Position: Q4 2024 in Review
Enterprise Financial Services Corp (EFSC) sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 194 shares — an estimated $204K sold.
Enterprise Financial Services Corp (EFSC) first reported a position in REGN in Q2 2013 and held it in 32 quarters. The position peaked at $204K in Q3 2024. 1,318 funds tracked by Wall St. Rank hold REGN as of Q4 2024.
- Enterprise Financial Services Corp (EFSC) reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
- Enterprise Financial Services Corp (EFSC) sold 194 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $204K.
- Enterprise Financial Services Corp (EFSC) first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 32 quarters.
- Enterprise Financial Services Corp (EFSC)'s Regeneron Pharmaceuticals position peaked at $204K in Q3 2024.
- 1,318 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.
Based on Enterprise Financial Services Corp (EFSC)'s 13F filing for Q4 2024, filed 7 Feb 2025.